. Author manuscript; available in PMC: 2012 Jul 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2010 Nov 30;17(7):1072–1078. doi: 10.1016/j.bbmt.2010.11.018

Table 2.

Pulmonary function & clinical characteristics of BOS patients at time of meeting NIH criteria based upon clinical recognition status

Measure	Concurrent n = 38		Late n = 14		Unrecognized n = 11		p-value^*	All Cases N = 63
	Median	Range	Median	Range	Median	Range	p-value^*	Median	Range
FEV₁ (%)	58%	(16%, 74%)	57%	(38%, 74%)	64%	(44%, 73%)	0.1750	59%	(16%, 74%)
SVC (%)	73%	(41%, 99%)	72%	(46%, 97%)	75%	(57%, 91%)	0.5871	73%	(41, 99%)
FEV₁/SVC ratio	0.61	(0.29, 0.69)	0.58	(0.46, 0.68)	0.64	(0.54, 0.69)	0.0646	0.63	(0.29, 0.69)
TLC (%)	99%	(75%, 153%)	96%	(64%, 120%)	90%	(66%, 119%)	0.3360	96%	(64, 153%)
RV (%)	155%	(65%, 334%)	113%	(62%, 195%)	116%	(57%, 163%)	0.0275	135%	(57%, 334%)
DLCO (%)	66%	(34%, 95%)	59%	(9%, 98%)	60%	(24%, 104%)	0.2896	63%	(9%, 104%)
LFS	9	(4, 12)	9	(4, 12)	8	(4, 11)	0.2282	9	(4, 12)

P-values were calculated using the Kruskal-Wallis test to compare the medians of the concurrent, late, and unrecognized groups.